tert-Butyl 4-(((6-chloropyridazin-3-yl)amino)methyl)piperidine-1-carboxylate

Catalog No. :
ACDMMM578
CAS No. :
544696-24-4
Molecular Formula :
C15H23ClN4O2
Molecular Weight :
326.83

IUPAC Name:tert-butyl 4-(((6-chloropyridazin-3-yl)amino)methyl)piperidine-1-carboxylate

tert-Butyl 4-(((6-chloropyridazin-3-yl)amino)methyl)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$449.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(((6-chloropyridazin-3-yl)amino)methyl)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(((6-chloropyridazin-3-yl)amino)methyl)piperidine-1-carboxylate
MDL No.MFCD09607522
Molecular FormulaC15H23ClN4O2
Molecular Weight326.83
SMILESO=C(N1CCC(CNC2=NN=C(Cl)C=C2)CC1)OC(C)(C)C
InChI KeyMDTKYNULOLUHLL-UHFFFAOYSA-N
Synonym4-[[(6-Chloro-3-pyridazinyl)amino]methyl]-1-piperidinecarboxylic acid tert-butyl ester;4-[(6-Chloro-pyridazin-3-ylaMino)-Methyl]-piperidine-1-carboxylic acid tert-butyl ester, 98+% C15H23ClN4O2, MW: 326.82;1-Piperidinecarboxylic acid, 4-[[(6-chloro-3-pyridazinyl)amino]methyl]-, 1,1-dimethylethyl ester
CAS No.544696-24-4

Synthetic Route by SureRoute

1. ACDMMM578 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHXEM378 route compound structure diagram
    ACHXEM378359629-16-6 In Stock
  2. Plus
  3. ACNROZ260 route compound structure diagram
    ACNROZ260141-30-0 In Stock
  4. Then
  5. ACDMMM578 route product structure diagram
    ACDMMM578544696-24-4
Inquiry

2. ACDMMM578 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHXEM378 route compound structure diagram
    ACHXEM378359629-16-6 In Stock
  2. Plus
  3. ACQFRX407 route compound structure diagram
    ACQFRX40789089-18-9 In Stock
  4. Then
  5. ACDMMM578 route product structure diagram
    ACDMMM578544696-24-4
Inquiry

Comments (0)